TEL
AVIV, Israel, April 26,
2023 /PRNewswire/ -- Chemomab Therapeutics Ltd.
(Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company
focused on the discovery and development of innovative therapeutics
for fibro-inflammatory diseases with high unmet need, today
announced that the company will participate in the Aegis Virtual
Conference being held May
2–May 4, 2023. Chemomab
management will present a corporate overview on Wednesday, May 3, 2023.
Aegis 2023 Virtual Investor Conference
Date:
|
May 3,
2023
|
Time:
|
9:00am EDT
|
Venue:
|
Virtual
|
Format:
|
Webcast -- Corporate
overview
|
Presenter:
|
Senior
management
|
Webcast
Link:
|
https://us02web.zoom.us/j/81590540881
|
Information:
|
mschiavellojr@aegiscap.com
|
In addition, Chemomab reported that its corporate development
team will be in Boston
June 5-8, 2023, participating in the
BIO International Convention's One-on-One Partnering™ event.
Registered attendees can click here to log in and schedule a
meeting with Chemomab.
About Chemomab Therapeutics
Chemomab is a clinical
stage biotechnology company discovering and developing innovative
therapeutics for fibro-inflammatory diseases with high unmet need.
Based on the unique and pivotal role of the chemokine CCL24 in
promoting fibrosis and inflammation, Chemomab developed CM-101, a
monoclonal antibody designed to neutralize CCL24 activity. In
preclinical and clinical studies to date, CM-101 appears safe, with
the potential to treat multiple severe and life-threatening
fibro-inflammatory diseases. Encouraging results from a Phase 2
biomarker study in NASH patients and an investigator study in
patients with severe lung injury were recently reported. A Phase 2
trial in primary sclerosing cholangitis patients is ongoing and a
Phase 2 systemic sclerosis trial is expected to begin around
midyear. For more information on Chemomab, visit chemomab.com.
Contacts:
|
|
|
|
Investors:
|
Investors & Media:
|
Irina
Koffler
|
Barbara
Lindheim
|
LifeSci Advisors,
LLC
|
Chemomab
Therapeutics
|
Phone: +1 (917)
734-7387
|
Consulting Vice
President, Investor & Public Relations
|
ir@chemomab.com
|
Strategic
Communications
|
|
barbara.lindheim@chemomab.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-present-at-2023-aegis-virtual-conference-301807799.html
SOURCE Chemomab Therapeutics, Ltd.